Physician profile
John D Bednar
NPI 1720373905
$674.65
in general payments reported to CMS, 2019-2025
16 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $173 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.23 | 2024-2025 | |
| Inspire Medical Systems, INC. | $71.24 | 2024-2025 | Inspire |
| Novo Nordisk INC | $64.13 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $58.82 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Harmony Biosciences LLC | $58.16 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $52.48 | 2025 | |
| Dexcom, INC. | $51.80 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $46.88 | 2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $34.97 | 2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.06 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $25.21 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.70 | 2024 | Breztri |
| Lilly USA, LLC | $23.20 | 2025 | Zepbound, Mounjaro |
| Mirum Pharmaceuticals, INC. | $21.12 | 2024 | Cholbam |
| Tolmar, INC. | $17.84 | 2025 | Jatenzo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.81 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bednar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.